Article

Acceptable Performance of the Abbott ID NOW Among Symptomatic Individuals with Confirmed COVID-19

2020-12-30

Abstract excerpt

<h4>INTRODUCTION</h4> Point of care diagnostic tests for SARS-CoV-2, such as the ID NOW, have great potential to help combat the COVID-19 pandemic. The ID NOW is approved by the United States Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in symptomatic individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 hour of specimen collection. However, clinical data on the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c34ce87b-2bb9-53a8-a8f0-d4bea7489295
DOI: 10.1101/2020.12.24.20248786

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acceptable Performance of the Abbott ID NOW Among Symptomatic Individuals with Confirmed COVID-19DOI 10.1101/2020.12.24.20248786Read

Evaluation of the ID NOW Among Symptomatic Individuals During the Omicron WaveSemantic proximity Read

Relative Sensitivity of ID NOW and RT-PCR for Detection of SARS-CoV-2 in an Ambulatory Population: Clinical Evaluation, Systematic Review and Meta-analysisSemantic proximity Read

Then and NOW: A Prospective Population-Level Validation of the Abbott ID NOW SARS-CoV-2 Device Implemented in Multiple Settings for Testing Asymptomatic and Symptomatic IndividualsSemantic proximity Read

Diagnostic accuracy and feasibility of a rapid SARS-CoV-2 antigen test in general practice – a prospective multicenter validation and implementation studySemantic proximity Read

Comparison of two commercial platforms and a laboratory developed test for detection of SARS-CoV-2 RNASemantic proximity Read

Accuracy of Rapid Point-of-Care Antibody Test in patients with suspected or confirmed COVID-19Semantic proximity Read

Clinical evaluation of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal health service drive-through testing siteSemantic proximity Read

Retrospective and prospective studies evaluating the performance of the SARS-Cov-2 “AQ+ COVID-19 Ag Rapid Test” from InTec on symptomatic and non-symptomatic patientsSemantic proximity Read

Real-life validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infectionSemantic proximity Read

Evaluation of seven different rapid methods for nucleic acid detection of SARS-COV-2 virusSemantic proximity Read

A Multi-Center Clinical Diagnostic Accuracy Study of Surestatus - an Affordable, WHO Emergency-Use-Listed, Rapid, Point-of-Care, Antigen-Detecting Diagnostic Test for SARS-CoV-2Semantic proximity Read

Standardization and Comparison of Emergency Use Authorized COVID-19 Assays and Testing LaboratoriesSemantic proximity Read